Treatment with the LTβR agonist or the LTβR ligand LIGHT, which had been targeted to the tumor vasculature by fusing it to a vascular zip code peptide, induced MECA79+ HEVs in various mouse tumor models, including those of breast cancer, neuroendocrine pancreatic tumors, and glioblastomas (107, 113–115). The gene discussed is LTBR; the disease is breast carcinoma.